CohBar, Inc. (CWBR) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
1455 ADAMS DRIVE, SUITE 2050 MENLO PARK, CA 94025 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 14,081 | 15,737 | 18,339 | 20,097 | 23,528 | 26,246 | |||
| Cash and cash equivalent | 5,392 | 5,931 | 4,211 | 2,878 | 1,564 | 4,992 | |||
| Short-term investments | 8,689 | 9,807 | 14,128 | 17,219 | 21,964 | 21,254 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | |||||||||
| Other undisclosed current assets | 237 | 481 | 683 | 1,068 | 375 | 701 | |||
| Total current assets: | 14,319 | 16,219 | 19,023 | 21,165 | 23,903 | 26,947 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 2 | 66 | 175 | 196 | 228 | 261 | |||
| Intangible assets, net (including goodwill), including: | 18 | 18 | 18 | 19 | 19 | 19 | |||
| Intangible assets, net (excluding goodwill) | 18 | 42 | 18 | 19 | 19 | 43 | |||
| Other undisclosed intangible assets, net (including goodwill) | (24) | (24) | |||||||
| Other noncurrent assets | 64 | 64 | 77 | 77 | 77 | 70 | |||
| Total noncurrent assets: | 84 | 147 | 270 | 291 | 324 | 350 | |||
| TOTAL ASSETS: | 14,402 | 16,366 | 19,293 | 21,457 | 24,227 | 27,296 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 582 | 508 | 350 | 385 | 777 | 681 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 113 | ||
| Accounts payable | 532 | 180 | 257 | 309 | 641 | 372 | |||
| Accrued liabilities | 50 | 328 | 92 | 77 | 137 | 196 | |||
| Debt | 766 | ||||||||
| Other undisclosed current liabilities | 241 | ||||||||
| Total current liabilities: | 582 | 508 | 350 | 385 | 777 | 1,689 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 317 | 526 | 197 | 359 | 446 | ||||
| Total liabilities: | 899 | 1,034 | 546 | 744 | 1,224 | 1,689 | |||
| Equity | |||||||||
| Equity, attributable to parent | 13,504 | 15,332 | 18,746 | 20,713 | 23,003 | 25,608 | |||
| Common stock | 3 | 3 | 3 | 87 | 87 | 86 | |||
| Additional paid in capital | 112,576 | 112,238 | 111,856 | 111,347 | 110,912 | 110,256 | |||
| Accumulated deficit | (99,075) | (96,909) | (93,113) | (90,721) | (87,996) | (84,734) | |||
| Total equity: | 13,504 | 15,332 | 18,746 | 20,713 | 23,003 | 25,608 | |||
| TOTAL LIABILITIES AND EQUITY: | 14,402 | 16,366 | 19,293 | 21,457 | 24,227 | 27,296 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | (2,906) | |||||||
| Operating expenses | (2,300) | (3,923) | (2,471) | (2,744) | (3,251) | (2,782) | ||
| Operating loss: | (2,300) | (3,923) | (2,471) | (2,744) | (3,251) | (2,782) | ||
| Nonoperating income (expense) | 134 | 126 | 79 | 19 | (11) | (11) | ||
| Investment income, nonoperating | (9) | (4) | ||||||
| Interest and debt expense | (2) | (8) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (2,166) | (3,797) | (2,392) | (2,725) | (3,264) | (2,800) | ||
| Income from equity method investments | 3,300 | |||||||
| Income (loss) from continuing operations before income taxes: | (2,166) | (3,797) | (2,392) | (2,725) | 36 | (2,800) | ||
| Other undisclosed income from continuing operations | 1,818 | |||||||
| Income (loss) from continuing operations: | (2,166) | (3,797) | (2,392) | (2,725) | 36 | (982) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (2,392) | (2,725) | 36 | (982) | |
| Other undisclosed net loss | (3,298) | (1,777) | ||||||
| Net loss: | (2,166) | (3,797) | (2,392) | (2,725) | (3,262) | (2,760) | ||
| Other undisclosed net loss attributable to parent | (33) | |||||||
| Net loss available to common stockholders, diluted: | (2,166) | (3,797) | (2,392) | (2,725) | (3,262) | (2,792) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (2,166) | (3,797) | (2,392) | (2,725) | (3,262) | (2,760) | ||
| Comprehensive loss, net of tax, attributable to parent: | (2,166) | (3,797) | (2,392) | (2,725) | (3,262) | (2,760) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.